Furthermore, the efficacy and safety of tirzepatide in children and adolescents, aged 10–17 years, with youth-onset T2D inadequately controlled with metformin and/or basal insulin were confirmed in the SURPASS-PEDS study [4,5,6,7,8,9,10]. The gene discussed is INS; the disease is type 2 diabetes mellitus.